Phase I
The possible addition of a new lithium-based drug to the list of available therapeutics is important because many physicians are reluctant to prescribe lithium.
Two investigational drugs have been taking the spotlight recently from Revive and Ascletis as they share news regarding their potential treatment against COVID-19.
Acadia Pharmaceuticals faces a major hurdle after top-line results from its study of ACP-044 for post-surgery pain failed to meet desired outcomes.
New Haven, Conn.-based BioXcel Therapeutics launched a wholly-owned subsidiary, OnkosXcel, to focus on oncology.
AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.
Weeks after Imara announced its plans to discontinue the development of tovinontrinein for sickle cell and beta-thalassemia and heart failure, the company has culled 83% of its workforce.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
There are an estimated 2.3 million people living with Multiple Sclerosis and hundreds of thousands more undiagnosed, adding up to an annual cost of nearly $85 billion for care in the United States.
BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.
The FDA granted Merck’s investigational 21-valent pneumococcal conjugate vaccine (V116) for IPD and pneumococcal pneumonia Breakthrough Therapy Designation.
PRESS RELEASES